Hughes Owen 4

What Happened

• Owen Hughes, a member of the Board of Directors of C4 Therapeutics, Inc. (CCCC), was granted a derivative award on 2026-06-24 for 62,000 shares. The filing shows an acquisition at $0.00 (no cash paid) — this is a grant of equity compensation, not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-06-24, 62,000 shares granted, $0.00 per share (derivative award).
• Vesting/exercisability: The award "shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders," subject to continued board service (footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Report filed 2026-06-26 (two days after the transaction), which appears to meet the SEC’s Form 4 timing requirements.
• No 10b5‑1 plan, tax withholding, or sale/exercise reported in this transaction.

Context

• This filing records an equity grant (likely a stock option award per the footnote) to a director as part of compensation. It does not represent an open‑market buy or sale and does not indicate immediate cash proceeds or a disposition of shares. Such grants are commonly part of director compensation packages and should be interpreted as routine corporate governance/equity compensation rather than a direct market sentiment signal.